Currently, clinical trials investigate the therapeutic benefit of immune checkpoint inhibitors, such as antibodies targeting programmed cell death protein 1 (PD-1) and its ligand PD-L1 in the primary and R/M setting for HNSCC (8). Here, CD274 is linked to head and neck squamous cell carcinoma.